-
公开(公告)号：US07244763B2
公开(公告)日：2007-07-17
申请号：US10774260
申请日：2004-02-06
申请人： Larry D. Bratton , Xue-Min Cheng , Noe Erasga , Gary F. Filzen , Andrew G. Geyer , Chitase Lee , Bharat K. Trivedi , Paul C. Unangst
发明人： Larry D. Bratton , Xue-Min Cheng , Noe Erasga , Gary F. Filzen , Andrew G. Geyer , Chitase Lee , Bharat K. Trivedi , Paul C. Unangst
IPC分类号： A61K31/235 , A61K31/38 , A61K31/35 , C07D405/00 , C07D261/06
CPC分类号： C07D213/74 , C07C59/72 , C07C62/34 , C07C323/20 , C07C323/21 , C07C323/22 , C07C323/25 , C07C323/62 , C07C2601/02 , C07C2602/08 , C07C2602/10 , C07C2603/18 , C07D213/34 , C07D215/36 , C07D261/08 , C07D263/57 , C07D263/58 , C07D307/79 , C07D311/58 , C07D333/22 , C07D333/60 , C07D405/12 , C07D413/12 , C07D417/12
摘要： This invention relates to compounds that alter PPAR activity. The invention also relates to pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing dyslipidemia, hypercholesterolemia, obesity, hyperglycemia, atherosclerosis, hypertriglyceridemia and hyperinsulinemia in a mammal. The present invention also relates to methods for making the disclosed compounds.
摘要翻译： 本发明涉及改变PPAR活性的化合物。 本发明还涉及化合物的药学上可接受的盐，包含该化合物或其盐的药学上可接受的组合物，以及使用它们作为治疗或预防哺乳动物血脂异常，高胆固醇血症，肥胖症，高血糖症，动脉粥样硬化，高甘油三酯血症和高胰岛素血症的治疗剂的方法 。 本发明还涉及制备所公开的化合物的方法。
-
公开(公告)号：US06867224B2
公开(公告)日：2005-03-15
申请号：US10324266
申请日：2002-12-19
IPC分类号： A61K31/426 , A61K31/427 , A61K31/4725 , A61P3/00 , A61P3/06 , A61P3/10 , A61P9/10 , C07D277/26 , C07D277/30 , C07D417/12
CPC分类号： C07D417/12 , C07D277/26
摘要： This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing hyperlipidemia and hypercholesteremia in a mammal. The present invention also discloses method for making the disclosed compounds.
摘要翻译： 本发明公开了改变PPAR活性的化合物。 本发明还公开了化合物的药学上可接受的盐，包含化合物或其盐的药学上可接受的组合物，以及使用它们作为治疗或预防哺乳动物高脂血症和高胆固醇血症的治疗剂的方法。 本发明还公开了制备所公开的化合物的方法。
-
公开(公告)号：US07109222B2
公开(公告)日：2006-09-19
申请号：US11025271
申请日：2004-12-24
IPC分类号： A61K31/426 , C07D277/30
CPC分类号： C07D417/12 , C07D277/26
摘要： This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing hyperlipidemia and hypercholesteremia in a mammal. The present invention also discloses method for making the disclosed compounds.
-
4.发明授权公开(公告)号：US06939875B2
公开(公告)日：2005-09-06
申请号：US10979617
申请日：2004-11-02
申请人： Bruce J. Auerbach , Larry D. Bratton , Gary F. Filzen , Andrew G. Geyer , Bharat K. Trivedi , Paul C. Unangst
发明人： Bruce J. Auerbach , Larry D. Bratton , Gary F. Filzen , Andrew G. Geyer , Bharat K. Trivedi , Paul C. Unangst
IPC分类号： A61K31/19 , A61K31/192 , A61K31/353 , A61K31/381 , A61K31/404 , A61K31/4168 , A61K31/4178 , A61K31/42 , A61K31/422 , A61K31/4245 , A61K31/44 , A61K31/4402 , A61K31/445 , A61K31/4525 , A61P3/04 , A61P3/06 , A61P3/10 , A61P9/10 , A61P35/00 , A61P43/00 , C07C27/02 , C07C51/09 , C07C59/135 , C07C59/70 , C07C59/72 , C07C315/04 , C07C317/22 , C07C319/20 , C07C323/19 , C07C323/20 , C07C323/21 , C07D209/10 , C07D211/14 , C07D211/18 , C07D213/20 , C07D213/30 , C07D213/32 , C07D231/12 , C07D233/68 , C07D235/18 , C07D261/08 , C07D271/06 , C07D271/10 , C07D295/092 , C07D307/79 , C07D311/58 , C07D333/54 , C07D405/06 , C07D405/10 , C07D405/12 , C07D413/04 , C07D413/12 , C07D521/00 , C07D213/02
CPC分类号： C07C323/20 , C07C59/70 , C07C59/72 , C07C317/22 , C07C323/19 , C07C2602/08 , C07C2603/18 , C07D209/10 , C07D211/14 , C07D213/30 , C07D213/32 , C07D231/12 , C07D233/56 , C07D233/68 , C07D235/18 , C07D249/08 , C07D261/08 , C07D271/06 , C07D271/10 , C07D295/088 , C07D307/79 , C07D311/58 , C07D333/54 , C07D405/12 , C07D413/04 , C07D413/12
摘要： This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing disipidemia, hypercholesteremia, obesity, eating disorders, hyperglycemia, atherosclerosis, hypertriglyceridemia, hyperinsulinemia and diabetes in a mammal as well as methods of supressing appetite and modulating leptin levels in a mammal. The present invention also discloses methods for making the disclosed compounds.
摘要翻译： 本发明公开了改变PPAR活性的化合物。 本发明还公开了化合物的药学上可接受的盐，包含化合物或其盐的药学上可接受的组合物，以及使用它们作为治疗或预防血脂异常，高胆固醇血症，肥胖，进食障碍，高血糖症，动脉粥样硬化，高甘油三酯血症，高胰岛素血症和 哺乳动物中的糖尿病以及抑制食欲和调节哺乳动物瘦素水平的方法。 本发明还公开了制备所公开的化合物的方法。
-
公开(公告)号：US06964983B2
公开(公告)日：2005-11-15
申请号：US10979629
申请日：2004-11-02
申请人： Bruce J. Auerbach , Larry D. Bratton , Gary F. Filzen , Andrew G. Geyer , Bharat K. Trivedi , Paul C. Unangst
发明人： Bruce J. Auerbach , Larry D. Bratton , Gary F. Filzen , Andrew G. Geyer , Bharat K. Trivedi , Paul C. Unangst
IPC分类号： A61K31/19 , A61K31/192 , A61K31/353 , A61K31/381 , A61K31/404 , A61K31/4168 , A61K31/4178 , A61K31/42 , A61K31/422 , A61K31/4245 , A61K31/44 , A61K31/4402 , A61K31/445 , A61K31/4525 , A61P3/04 , A61P3/06 , A61P3/10 , A61P9/10 , A61P35/00 , A61P43/00 , C07C27/02 , C07C51/09 , C07C59/135 , C07C59/70 , C07C59/72 , C07C315/04 , C07C317/22 , C07C319/20 , C07C323/19 , C07C323/20 , C07C323/21 , C07D209/10 , C07D211/14 , C07D211/18 , C07D213/20 , C07D213/30 , C07D213/32 , C07D231/12 , C07D233/68 , C07D235/18 , C07D261/08 , C07D271/06 , C07D271/10 , C07D295/092 , C07D307/79 , C07D311/58 , C07D333/54 , C07D405/06 , C07D405/10 , C07D405/12 , C07D413/04 , C07D413/12 , C07D521/00 , C07C51/00
CPC分类号： C07C323/20 , C07C59/70 , C07C59/72 , C07C317/22 , C07C323/19 , C07C2602/08 , C07C2603/18 , C07D209/10 , C07D211/14 , C07D213/30 , C07D213/32 , C07D231/12 , C07D233/56 , C07D233/68 , C07D235/18 , C07D249/08 , C07D261/08 , C07D271/06 , C07D271/10 , C07D295/088 , C07D307/79 , C07D311/58 , C07D333/54 , C07D405/12 , C07D413/04 , C07D413/12
摘要： This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing disipidemia, hypercholesteremia, obesity, eating disorders, hyperglycemia, atherosclerosis, hypertriglyceridemia, hyperinsulinemia and diabetes in a mammal as well as methods of supressing appetite and modulating leptin levels in a mammal. The present invention also discloses methods for making the disclosed compounds.
-
6.发明授权公开(公告)号：US06875780B2
公开(公告)日：2005-04-05
申请号：US10347749
申请日：2003-01-22
申请人： Bruce J. Auerbach , Larry D. Bratton , Gary F. Filzen , Andrew G. Geyer , Bharat K. Trivedi , Paul C. Unangst
发明人： Bruce J. Auerbach , Larry D. Bratton , Gary F. Filzen , Andrew G. Geyer , Bharat K. Trivedi , Paul C. Unangst
IPC分类号： A61K31/19 , A61K31/192 , A61K31/353 , A61K31/381 , A61K31/404 , A61K31/4168 , A61K31/4178 , A61K31/42 , A61K31/422 , A61K31/4245 , A61K31/44 , A61K31/4402 , A61K31/445 , A61K31/4525 , A61P3/04 , A61P3/06 , A61P3/10 , A61P9/10 , A61P35/00 , A61P43/00 , C07C27/02 , C07C51/09 , C07C59/135 , C07C59/70 , C07C59/72 , C07C315/04 , C07C317/22 , C07C319/20 , C07C323/19 , C07C323/20 , C07C323/21 , C07D209/10 , C07D211/14 , C07D211/18 , C07D213/20 , C07D213/30 , C07D213/32 , C07D231/12 , C07D233/68 , C07D235/18 , C07D261/08 , C07D271/06 , C07D271/10 , C07D295/092 , C07D307/79 , C07D311/58 , C07D333/54 , C07D405/06 , C07D405/10 , C07D405/12 , C07D413/04 , C07D413/12 , C07D521/00 , C07D213/02 , A61K31/47
CPC分类号： C07C323/20 , C07C59/70 , C07C59/72 , C07C317/22 , C07C323/19 , C07C2602/08 , C07C2603/18 , C07D209/10 , C07D211/14 , C07D213/30 , C07D213/32 , C07D231/12 , C07D233/56 , C07D233/68 , C07D235/18 , C07D249/08 , C07D261/08 , C07D271/06 , C07D271/10 , C07D295/088 , C07D307/79 , C07D311/58 , C07D333/54 , C07D405/12 , C07D413/04 , C07D413/12
摘要： This invention relates to compounds that alter PPAR activity. The invention also relates to pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing dyslipidemia, hypercholesterolemia, obesity, hyperglycemia, atherosclerosis, hypertriglyceridemia and hyperinsulinemia in a mammal. The present invention also relates to methods for making the disclosed compounds.
摘要翻译： 本发明涉及改变PPAR活性的化合物。 本发明还涉及化合物的药学上可接受的盐，包含该化合物或其盐的药学上可接受的组合物，以及使用它们作为治疗或预防哺乳动物血脂异常，高胆固醇血症，肥胖症，高血糖症，动脉粥样硬化，高甘油三酯血症和高胰岛素血症的治疗剂的方法 。 本发明还涉及制备所公开的化合物的方法。
-
7.再颁专利公开(公告)号：USRE39916E1
公开(公告)日：2007-11-06
申请号：US11288022
申请日：2005-11-28
申请人： Bruce J. Auerbach , Larry D. Bratton , Gary Filzen , Andrew G. Geyer , Bharat K. Trivedi , Paul C. Unangst
发明人： Bruce J. Auerbach , Larry D. Bratton , Gary Filzen , Andrew G. Geyer , Bharat K. Trivedi , Paul C. Unangst
IPC分类号： A61K31/44 , C07D213/02
CPC分类号： C07C323/20 , C07C59/70 , C07C59/72 , C07C317/22 , C07C323/19 , C07C2602/08 , C07C2603/18 , C07D209/10 , C07D211/14 , C07D213/30 , C07D213/32 , C07D231/12 , C07D233/56 , C07D233/68 , C07D235/18 , C07D249/08 , C07D261/08 , C07D271/06 , C07D271/10 , C07D295/088 , C07D307/79 , C07D311/58 , C07D333/54 , C07D405/12 , C07D413/04 , C07D413/12
摘要： This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds of their salts, and methods of using them as therapeutic agents for treating or preventing disipidemia, hypercholesteremia, obesity, eating disorders, hyperglycemia, atherosclerosis, hypertriglyceridemia, hyperinsulinemia and diabetes in a mammal as well as methods of suppressing appetite and modulating leptin levels in a mammal. The present invention also discloses methods for making the disclosed compounds.
摘要翻译： 本发明公开了改变PPAR活性的化合物。 本发明还公开了化合物的药学上可接受的盐，包含其盐的化合物的药学上可接受的组合物，以及使用它们作为治疗或预防血脂异常，高胆固醇血症，肥胖症，进食障碍，高血糖症，动脉粥样硬化，高甘油三酯血症，高胰岛素血症和 哺乳动物中的糖尿病以及抑制哺乳动物的食欲和调节瘦素水平的方法。 本发明还公开了制备所公开的化合物的方法。
-
公开(公告)号：US20080269293A1
公开(公告)日：2008-10-30
申请号：US11843431
申请日：2007-08-22
申请人： Liguo Chi , Chulho Choi , Andrew G. Geyer , Robert M. Kennedy , Jeffery A. Pfefferkorn , Roy T. Winters
发明人： Liguo Chi , Chulho Choi , Andrew G. Geyer , Robert M. Kennedy , Jeffery A. Pfefferkorn , Roy T. Winters
IPC分类号： A61K31/4152 , C07D231/22 , A61K31/4439 , A61P9/10 , A61P7/02 , A61K31/4453 , C07D401/12
CPC分类号： C07D231/22 , C07D231/14 , C07D231/24 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D413/12
摘要： This invention relates to novel compounds of formula (I) or stereoisomers or pharmaceutically acceptable salts thereof wherein Y, R1 through R9, and X1 through X7 are as defined in the specification, pharmaceutical compositions containing said compounds useful as P2Y1 antagonists, and to methods of treating thromboembolic disorders.
摘要翻译： 本发明涉及新的式（I）化合物或其立体异构体或其药学上可接受的盐，其中Y，R 1至R 9和X 1 通过X 7如本说明书中所定义，含有用作P2Y 1 N拮抗剂的所述化合物的药物组合物，以及治疗血栓栓塞性疾病的方法。
-
公开(公告)号：US06284796B1
公开(公告)日：2001-09-04
申请号：US09236254
申请日：1999-01-25
申请人： Andrew G. Geyer , William J. McClellan , Todd W. Rockway , Kent D. Stewart , Moshe Weitzberg , Michael D. Wendt
发明人： Andrew G. Geyer , William J. McClellan , Todd W. Rockway , Kent D. Stewart , Moshe Weitzberg , Michael D. Wendt
IPC分类号： A61K31165
CPC分类号： C07D213/74 , C07B2200/07 , C07B2200/09 , C07C257/18 , C07C259/18 , C07C271/22 , C07C271/28 , C07C271/30 , C07C271/64 , C07C275/40 , C07C275/42 , C07C275/64 , C07C311/13 , C07C311/16 , C07C323/60 , C07C323/62 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/10 , C07C2601/14 , C07C2602/08 , C07D217/02 , C07D231/12 , C07D239/42 , C07D241/18 , C07D277/30 , C07D295/088 , C07D295/155 , C07D307/18 , C07D307/54 , C07D307/64 , C07D307/79 , C07D333/24
摘要： Compounds having the formula are inhibitors of urokinase and are useful in the treatment of diseases in which urokinase plays a role. Also disclosed are urokinase-inhibiting compositions and a method of inhibiting urokinase in a mammal.
摘要翻译： 具有该化学式的化合物是尿激酶的抑制剂，并且可用于治疗尿激酶起作用的疾病。 还公开了尿激酶抑制组合物和抑制哺乳动物尿激酶的方法。
-
公开(公告)号：US06258822B1
公开(公告)日：2001-07-10
申请号：US09129989
申请日：1998-08-06
申请人： Andrew G. Geyer , William J. McClellan , Todd W. Rockway , Kent D. Stewart , Moshe Weitzberg , Michael D. Wendt
发明人： Andrew G. Geyer , William J. McClellan , Todd W. Rockway , Kent D. Stewart , Moshe Weitzberg , Michael D. Wendt
IPC分类号： A61K31505
CPC分类号： C07D213/74 , C07B2200/07 , C07B2200/09 , C07C257/18 , C07C259/18 , C07C271/22 , C07C271/28 , C07C271/30 , C07C271/64 , C07C275/40 , C07C275/42 , C07C275/64 , C07C311/13 , C07C311/16 , C07C323/60 , C07C323/62 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/10 , C07C2601/14 , C07C2602/08 , C07D217/02 , C07D231/12 , C07D239/42 , C07D241/18 , C07D277/30 , C07D295/088 , C07D295/155 , C07D307/18 , C07D307/54 , C07D307/64 , C07D307/79 , C07D333/24
摘要： Compounds having the formula are inhibitors of urokinase and are useful in the treatment of diseases in which urokinase plays a role. Also disclosed are urokinase-inhibiting compositions and a method of inhibiting urokinase in a mammal.
摘要翻译： 具有该化学式的化合物是尿激酶的抑制剂，并且可用于治疗尿激酶起作用的疾病。 还公开了尿激酶抑制组合物和抑制哺乳动物尿激酶的方法。
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.044 秒)
